TriMix MEL

N/A

Report date: 2026/04/13 20:02:18

Base Information

Drug NameTriMix MEL
Drug Alias NameTriMix immunotherapiesTriMix immunotherapies - eTheRNA immunotherapiesECI-001ECI-003ECI-006
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Gene therapy > mRNA
Mechanisms of ActionDendritic cells modulatorsCytotoxic T lymphocytes stimulants
TargetsCD40 ligandCD70 antigenToll like receptor 4 +[8] 
Therapy Area/IndicationsXerophthalmiaLiver NeoplasmsBreast Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumSpain
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesVrije Universiteit Brussel
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of SevilleVrije Universiteit Brussel
Inactive CompanieseTheRNA Immunotherapies NV
Active IndicationsXerophthalmiaLiver NeoplasmsBreast Neoplasms +[4] 
Inactive IndicationsMelanoma

Other Information

ATC CodeN/A
Related LinksN/A